Caliway Biopharmaceuticals Co., Ltd. (TWSE: 6919)
Health Care · Pharmaceuticals · TW
NT$77.50
-3.00% today · -52.7% 1Y
Caliway Biopharmaceuticals Co., Ltd. (TWSE: 6919) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $3.77B and employs 20 people.
Over the last twelve months the share price has lost 52.7%, trading between 75.10 and 188.00.
Tweenvest scores Caliway Biopharmaceuticals Co., Ltd. across four factors: quality 42/100, value 68/100, growth 64/100. Its strongest factor is value.
6919 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.77B
- Revenue (TTM)
- $923.87K
- P/E
- —
- EPS
- -0.17
- Dividend yield
- —
- Beta (5Y)
- 1.14
- 52-week high
- NT$188.00
- 52-week low
- NT$75.10
- Avg volume (3M)
- —
- Shares outstanding
- 1.56B
- Employees
- 20
- Next earnings
- —
About Caliway Biopharmaceuticals Co., Ltd.
Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated to developing pharmaceuticals primarily in the fields of aesthetic medicine and chronic inflammation. Its lead investigational drug, CBL-514, is currently undergoing Phase 2 clinical trials, targeting non-surgical fat reduction, Dercum's disease, and cellulite. Beyond this, the firm is also progressing CBA-539 through preclinical exploration for potential applications in central obesity, hyperpigmentation, and skin aging. The company's offerings also extend to dietary supplements. Established in 2012, Caliway Biopharmaceuticals operates from its headquarters in New Taipei City, Taiwan.
- ISIN
- TW0006919004
- Founded
- 2012
- Listed since
- Dec 26, 2022
- Exchange
- Taiwan Stock Exchange
- Currency
- TWD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Zhejiang Huahai Pharmaceutical Co., Ltd.SHSE: 600521 | $3.88B | CN¥17.45 | +6.79% |
| Shijiazhuang Yiling Pharmaceutical Co., Ltd.SZSE: 002603 | $3.87B | CN¥15.53 | +1.17% |
| Camurus AB (publ)OM: CAMX | $3.81B | Skr641.00 | +5.43% |
| Hypera S.A.BOVESPA: HYPE3 | $3.81B | R$26.93 | +0.86% |
| Hubei Jumpcan Pharmaceutical Co., Ltd.SHSE: 600566 | $3.67B | CN¥26.70 | +2.61% |
| Regencell Bioscience Holdings LimitedNasdaqCM: RGC | $3.64B | $7.35 | +7.77% |
| Organon & Co.NYSE: OGN | $3.63B | $13.81 | +0.44% |
| Emcure Pharmaceuticals LimitedNSEI: EMCURE | $3.59B | Rs1,833.50 | -5.71% |
Figures last refreshed Oct 11, 2026.